PL3061747T3 - Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne - Google Patents
Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczneInfo
- Publication number
- PL3061747T3 PL3061747T3 PL14854930T PL14854930T PL3061747T3 PL 3061747 T3 PL3061747 T3 PL 3061747T3 PL 14854930 T PL14854930 T PL 14854930T PL 14854930 T PL14854930 T PL 14854930T PL 3061747 T3 PL3061747 T3 PL 3061747T3
- Authority
- PL
- Poland
- Prior art keywords
- preparing same
- ketone derivatives
- pharmaceutical application
- pyridic
- pyridic ketone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310512377 | 2013-10-25 | ||
| PCT/CN2014/085976 WO2015058589A1 (zh) | 2013-10-25 | 2014-09-05 | 吡啶酮类衍生物、其制备方法及其在医药上的应用 |
| EP14854930.6A EP3061747B1 (en) | 2013-10-25 | 2014-09-05 | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3061747T3 true PL3061747T3 (pl) | 2021-07-19 |
Family
ID=52992223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14854930T PL3061747T3 (pl) | 2013-10-25 | 2014-09-05 | Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9914703B2 (pl) |
| EP (1) | EP3061747B1 (pl) |
| JP (1) | JP6403172B2 (pl) |
| KR (1) | KR102222569B1 (pl) |
| CN (1) | CN104936945B (pl) |
| AU (1) | AU2014339527B2 (pl) |
| BR (1) | BR112016007396B1 (pl) |
| CA (1) | CA2927635C (pl) |
| ES (1) | ES2868450T3 (pl) |
| MX (1) | MX377816B (pl) |
| PL (1) | PL3061747T3 (pl) |
| PT (1) | PT3061747T (pl) |
| RU (1) | RU2667892C2 (pl) |
| TW (1) | TWI662026B (pl) |
| WO (1) | WO2015058589A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX382056B (es) * | 2015-03-27 | 2025-03-13 | Jiangsu Hengrui Medicine Co | P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. |
| CN104892499B (zh) * | 2015-06-26 | 2017-07-21 | 江西省科学院应用化学研究所 | 一种2‑吡啶酮类衍生物的合成方法 |
| JP2019535696A (ja) * | 2016-11-25 | 2019-12-12 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピリドン誘導体の医薬組成物およびその製造方法 |
| WO2018099424A1 (zh) * | 2016-12-01 | 2018-06-07 | 江苏恒瑞医药股份有限公司 | 一种吡啶酮类衍生物的制备方法及其中间体 |
| CN108314645A (zh) * | 2017-01-18 | 2018-07-24 | 上海映诺济生物科技有限公司 | 一类具有抗细胞增殖活性的化合物、制备方法和用途 |
| CA3067941C (en) * | 2017-06-23 | 2020-08-18 | Cstone Pharmaceuticals | Coumarin-like cyclic compound as mek inhibitor and use thereof |
| CN112912380B (zh) * | 2018-12-21 | 2023-08-11 | 基石药业（苏州）有限公司 | 一种mek抑制剂的晶型、无定形及其应用 |
| CN113423398A (zh) * | 2019-01-29 | 2021-09-21 | 贝达药业股份有限公司 | Mek抑制剂及其在医药上的应用 |
| CN111514140B (zh) * | 2019-02-01 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TW202114994A (zh) * | 2019-07-29 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法 |
| WO2021047573A1 (zh) * | 2019-09-11 | 2021-03-18 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤的药物中的用途 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CN111848613B (zh) * | 2020-08-11 | 2021-09-24 | 山东大学 | 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用 |
| CN117820248A (zh) * | 2021-04-14 | 2024-04-05 | 盐野义制药株式会社 | 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 |
| CA3229566A1 (en) * | 2021-08-17 | 2023-02-23 | Kanaph Therapeutics Inc. | Sos1 inhibitor and use thereof |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| CN120441478A (zh) * | 2024-02-07 | 2025-08-08 | 成都赜灵生物医药科技有限公司 | 一种六元内酰胺类化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002354575A1 (en) * | 2001-07-12 | 2003-01-29 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| AU2005252110B2 (en) * | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| SG177981A1 (en) * | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| ES2354916T3 (es) * | 2006-02-22 | 2011-03-21 | F. Hoffmann-La Roche Ag | Inhibidores de quinasa basados en la hidantoína. |
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| US20120238599A1 (en) * | 2011-03-17 | 2012-09-20 | Chemizon, A Division Of Optomagic Co., Ltd. | Heterocyclic compounds as mek inhibitors |
| WO2012162293A1 (en) | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| KR20140138910A (ko) * | 2012-03-14 | 2014-12-04 | 루핀 리미티드 | 헤테로사이클릴 화합물 |
-
2014
- 2014-09-05 BR BR112016007396-7A patent/BR112016007396B1/pt not_active IP Right Cessation
- 2014-09-05 JP JP2016518444A patent/JP6403172B2/ja not_active Expired - Fee Related
- 2014-09-05 US US15/030,125 patent/US9914703B2/en not_active Expired - Fee Related
- 2014-09-05 WO PCT/CN2014/085976 patent/WO2015058589A1/zh not_active Ceased
- 2014-09-05 ES ES14854930T patent/ES2868450T3/es active Active
- 2014-09-05 RU RU2016118753A patent/RU2667892C2/ru active
- 2014-09-05 PL PL14854930T patent/PL3061747T3/pl unknown
- 2014-09-05 KR KR1020167012819A patent/KR102222569B1/ko not_active Expired - Fee Related
- 2014-09-05 CN CN201480003661.8A patent/CN104936945B/zh active Active
- 2014-09-05 CA CA2927635A patent/CA2927635C/en not_active Expired - Fee Related
- 2014-09-05 PT PT148549306T patent/PT3061747T/pt unknown
- 2014-09-05 EP EP14854930.6A patent/EP3061747B1/en active Active
- 2014-09-05 AU AU2014339527A patent/AU2014339527B2/en not_active Ceased
- 2014-09-05 MX MX2016004742A patent/MX377816B/es unknown
- 2014-09-25 TW TW103133170A patent/TWI662026B/zh not_active IP Right Cessation
-
2017
- 2017-09-28 US US15/719,138 patent/US10064848B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2868450T3 (es) | 2021-10-21 |
| KR102222569B1 (ko) | 2021-03-05 |
| CN104936945B (zh) | 2017-11-03 |
| MX377816B (es) | 2025-03-11 |
| US20160244410A1 (en) | 2016-08-25 |
| TWI662026B (zh) | 2019-06-11 |
| CA2927635C (en) | 2021-07-20 |
| RU2016118753A (ru) | 2017-11-29 |
| PT3061747T (pt) | 2021-05-04 |
| KR20160074554A (ko) | 2016-06-28 |
| US20180016236A1 (en) | 2018-01-18 |
| US9914703B2 (en) | 2018-03-13 |
| RU2667892C2 (ru) | 2018-09-25 |
| RU2016118753A3 (pl) | 2018-05-25 |
| BR112016007396B1 (pt) | 2021-01-19 |
| AU2014339527B2 (en) | 2018-07-19 |
| AU2014339527A1 (en) | 2016-05-12 |
| HK1212980A1 (zh) | 2016-06-24 |
| EP3061747A1 (en) | 2016-08-31 |
| WO2015058589A1 (zh) | 2015-04-30 |
| JP2016534027A (ja) | 2016-11-04 |
| BR112016007396A2 (pt) | 2017-08-01 |
| CN104936945A (zh) | 2015-09-23 |
| JP6403172B2 (ja) | 2018-10-10 |
| EP3061747A4 (en) | 2017-05-10 |
| CA2927635A1 (en) | 2015-04-30 |
| US10064848B2 (en) | 2018-09-04 |
| EP3061747B1 (en) | 2021-04-07 |
| TW201518278A (zh) | 2015-05-16 |
| MX2016004742A (es) | 2016-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3061747T3 (pl) | Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne | |
| PL3486242T3 (pl) | Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne | |
| HRP20161202T8 (hr) | Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| PL2829539T3 (pl) | Nowe pochodne pirolu, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające | |
| EP3378859A4 (en) | Benzofuran derivative, preparation method thereof and use thereof in medicine | |
| EP2947084B8 (en) | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | |
| EP3040331A4 (en) | Tetrahydrocyclopentapyrrole derivative and preparation method therefor | |
| PT3064498T (pt) | Derivados de pirazolopirimidona ou de pirrolotriazona, método de preparação dos mesmos, e aplicações farmacêuticas dos mesmos | |
| LT2998296T (lt) | Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas | |
| EP3181553A4 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
| EP3231802A4 (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof | |
| SG11201604222YA (en) | Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use | |
| EP3072893A4 (en) | Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof | |
| ZA201601343B (en) | Vancomycin derivative, and preparation method and application thereof | |
| PL3055679T3 (pl) | Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć | |
| EP3072895A4 (en) | Phillygenol sulphate and derivative thereof, and preparation method and application thereof | |
| EP3037099A4 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| IL243227A0 (en) | History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them | |
| EP2955174A4 (en) | HOMOSERIN LACTONE DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | |
| IL242543B (en) | The history of tylosin and a method for its preparation | |
| DK3091005T3 (da) | 1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf | |
| EP2952519A4 (en) | PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | |
| EP3087980A4 (en) | Double-layer tablet and preparation method thereof | |
| EP3056491A4 (en) | Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof | |
| EP3052484A4 (en) | Sulfonylindole derivatives and method for preparing the same |